<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01792804</url>
  </required_header>
  <id_info>
    <org_study_id>Uni-Koeln-1400</org_study_id>
    <secondary_id>2013-000577-77</secondary_id>
    <nct_id>NCT01792804</nct_id>
  </id_info>
  <brief_title>Staphylococcus Aureus Bacteremia Antibiotic Treatment Options</brief_title>
  <acronym>SABATO</acronym>
  <official_title>Early Oral Switch Therapy in Low-risk Staphylococcus Aureus Bloodstream Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heinrich-Heine University, Duesseldorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Heinrich-Heine University, Duesseldorf</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Increasing resistance to antibiotic agents has been recognized as a major health problem
      worldwide that will even aggravate due to the lack of new antimicrobial agents within the
      next decade [1]. This threat underscores the need to maximize clinical utility of existing
      antibiotics, through more rational prescription, e.g. optimizing duration of treatment.

      Staphylococcus aureus bloodstream infection (SAB) is a common disease with about 200,000
      cases occurring annually in Europe [2]. A course of at least 14 days of intravenous
      antimicrobials is considered standard therapy [3-5] in &quot;uncomplicated&quot; SAB. This relatively
      long course serves to prevent SAB-related complications (such as endocarditis and vertebral
      osteomyelitis) that may result from hematogenous dissemination to distant sites. However,
      there is insufficient evidence that a full course of intravenous antibiotic therapy is always
      required in patients with a low risk of SAB-related complications.

      In a multicenter, open-label, randomized controlled trial we aim to demonstrate that an early
      switch from intravenous to oral antimicrobial therapy is non-inferior to a conventional
      14-days course of intravenous therapy regarding efficacy and safety. An early switch from
      intravenous to oral therapy would provide several benefits such as earlier discharge, fewer
      adverse reactions associated with intravenous therapy, increased quality of life, and cost
      savings.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. WHO. WHO Global Strategy for Containment of Antimicrobial Resistance.: World Health
           Organization, 2001.

        2. Kern WV. Management of Staphylococcus aureus bacteremia and endocarditis: progresses and
           challenges. Curr Opin Infect Dis 2010;23(4):346-58.

        3. Gemmell CG, Edwards DI, Fraise AP, Gould FK, Ridgway GL, Warren RE. Guidelines for the
           prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA)
           infections in the UK. J Antimicrob Chemother 2006;57(4):589-608.

        4. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious
           Diseases Society of America for the treatment of methicillin-resistant Staphylococcus
           aureus infections in adults and children. Clin Infect Dis 2011;52(3):e18-55.

        5. Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and
           management of intravascular catheter-related infection: 2009 Update by the Infectious
           Diseases Society of America. Clin Infect Dis 2009;49(1):1-45.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SAB-related complications</measure>
    <time_frame>90 days</time_frame>
    <description>S. aureus bloodstream infection-related complications (relapsing SAB, deep-seated infection with S. aureus, or attributable mortality) within 90 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>90 days</time_frame>
    <description>Length of hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>14, 30, and 90 days</time_frame>
    <description>Survival at 14, 30, and 90 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications of intravenous therapy</measure>
    <time_frame>90 days</time_frame>
    <description>Complications of intravenous therapy, such as thrombophlebitis.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Clostridium difficile associated diarrhea (CDAD)</measure>
    <time_frame>90 days</time_frame>
    <description>Clostridium difficile associated diarrhea (CDAD)</description>
  </other_outcome>
  <other_outcome>
    <measure>AEs and SAEs</measure>
    <time_frame>90 days</time_frame>
    <description>Adverse events</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">430</enrollment>
  <condition>Staphylococcus Aureus Infection</condition>
  <arm_group>
    <arm_group_label>Orally administered antibiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First choice (MRSA and MSSA): trimethoprim-sulfamethoxazole, or Second choice (MSSA): clindamycin, or Second choice (MRSA): linezolid administered for 7-9 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenously administered antibiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First choice (MSSA): flucloxacillin [Spain: cloxacillin], or cefazolin or Second choice (MSSA): vancomycin, or First choice (MRSA): vancomycin, or Second choice (MRSA): daptomycin administered for 7-9 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trimethoprim-Sulfamethoxazole</intervention_name>
    <description>study drug 1</description>
    <arm_group_label>Orally administered antibiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clindamycin</intervention_name>
    <description>study drug 2</description>
    <arm_group_label>Orally administered antibiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linezolid</intervention_name>
    <description>study drug 3</description>
    <arm_group_label>Orally administered antibiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flucloxacillin</intervention_name>
    <description>study drug 4</description>
    <arm_group_label>Intravenously administered antibiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cloxacillin</intervention_name>
    <description>study drug 5</description>
    <arm_group_label>Intravenously administered antibiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin</intervention_name>
    <description>study drug 6</description>
    <arm_group_label>Intravenously administered antibiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daptomycin</intervention_name>
    <description>study drug 7</description>
    <arm_group_label>Intravenously administered antibiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefazolin</intervention_name>
    <description>study drug 8</description>
    <arm_group_label>Intravenously administered antibiotic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age at least 18 years

          -  Not legally incapacitated

          -  Written informed consent from the trial subject has been obtained

          -  Blood culture positive for S. aureus not considered to represent contamination

          -  At least one negative follow-up blood culture obtained within 24-96 hours after the
             start of adequate antimicrobial therapy to rule out persistent bacteremia and Absence
             of a blood culture positive for S. aureus at the same time or thereafter.

          -  Five to seven full days of appropriate i.v. antimicrobial therapy administered prior
             to randomization documented in the patient Chart. Appropriate therapy has all of the
             following characteristics:

               1. Antimicrobial therapy has to be initiated within 72h after the first positive
                  blood culture was drawn.

               2. Provided in-vitro susceptibility and adequate dosing (as judged by the PI)
                  preferred agents for pre-randomization antimicrobial therapy are flucloxacillin,
                  cloxacillin, vancomycin and daptomycin. However, the following antimicrobials are
                  allowed:

                    -  MSSR: penicillinase-resistant penicillins (e.g. flucloxacillin,
                       cloxacillin), β-lactam plus β-lactamase-inhibitors (e.g.
                       ampicillin+sulbactam, piperacillin+tazobactam), cephalosporins (except
                       ceftazidime), carbapenems, clindamycin, fluoroquinolones,
                       trimethoprimsulfamethoxazole, doxycycline, tigecycline, vancomycin,
                       teicoplanin, telavancin, linezolid, daptomycin, ceftaroline, ceftobiprole,
                       and macrolides.

                    -  MRSA: vancomycin, teicoplanin, telavancin, fluoroquinolones, clindamycin,
                       trimethoprim-sulfamethoxazole, doxycycline, tigecycline, linezolid,
                       daptomycin, macrolides, ceftaroline, and ceftobiprole.

        Exclusion Criteria:

          -  Polymicrobial bloodstream infection, defined as isolation of pathogens other than S.
             aureus from a blood culture obtained in the time from two days prior to the first
             positive blood culture with S. aureus until randomization. Common skin contaminants
             (coagulase-negative staphylococci, diphtheroids, Bacillus spp., and Propionibacterium
             spp.) detected in one of several blood cultures will not be considered to represent
             polymicrobial infection

          -  Recent history (within 3 months) of prior S. aureus bloodstream infection

          -  In vitro resistance of S. aureus to all oral or all i.v. study drugs

          -  Contraindications for all oral or all i.v. study drugs

          -  Previously planned Treatment with active drug against S. aureus during Intervention
             Phase (e.g. cotrimoxazol prophylaxis)

          -  Signs and symptoms of complicated SAB as judged by an ID physician. Complicated
             infection is defined as at least one of the follwoing:

               -  deep-seated focus: e.g. endocarditis, pneumonia, undrained abscess, empyema, and
                  Osteomyelitis

               -  septic shock, as defined by the AACP criteria (23), within 4 days before
                  randomization

               -  prolonged bacteremia: positive follow-up blood culture more than 72h after the
                  start of adequate antimicrobial therapy

               -  body temperature &gt;38 °C on two separate days within 48h before randomization

          -  Presence of the following non-removable foreign bodies (if not removed 2 days or more
             before randomization):

               -  prosthetic heart valve

               -  deep-seated vascular graft with foreign material (e.g. PTFE or dacron graft).
                  Hemodialysis shunts are not considered deep-seated vascular grafts.

               -  ventriculo-atrial shunt

          -  Presence of a prosthetic joint (if not removed 2 days or more before randomization).
             This is not an exclusion criterion, if all of the following conditions are fulfilled:

               -  prosthetic joint was implanted at least 6 months prior, and

               -  catheter-related infection, skin and soft tissue infection, or surgical wound
                  infection is present (as defined below), and

               -  joint infection unlikely (no clinical or imaging signs)

          -  Presence of a pacemaker or an automated implantable cardioverter Defibrillator (AICD)
             device (if not removed 2 days or more before randomization). This is not an exclusion
             criterion, if all of the following conditions are fulfilled:

               -  pacemaker or AICD was implanted at least 6 months prior, and

               -  catheter-related infection, skin and soft tissue infection, or surgical wound
                  infection is present (as defined below), and

               -  no clinical signs of infective endocarditis, and

               -  infective endocarditis unlikely by echocardiography (preferably TEE), and

               -  pocket infection unlikely (no clinical or imaging signs)

          -  Failure to remove any intravascular catheter which was present when first positive
             blood culture was drawn within 4 days of the first positive blood culture

          -  Severe liver disease. This is not an exclusion criterion, if the following condition
             is fulfilled:

             - catheter-related infection, skin and soft tissue infection, or surgical wound
             infection is present

          -  End-stage renal disease. This is not an exclusion criterion, if all of the following
             conditions are fulfilled:

               -  catheter-related infection, skin and soft tissue infection, or surgical wound
                  infection is present (as defined below), and

               -  no clinical signs of infective endocarditis, and

               -  infective endocarditis unlikely by echocardiography (preferably TEE), and

               -  in patients with a hemodialysis shunt with a non-removable foreign body (e.g.
                  synthetic PTFE loop): no clinical signs of a shunt infection

          -  Severe immunodeficiency

               -  primary immunodeficiency disorders

               -  neutropenia (&lt;500 neutrophils/μl) at randomization or neutropenia expected during
                  intervention phase due to immunosuppressive treatment

               -  uncontrolled disease in HIV-positive patients

               -  high-dose steroid therapy (&gt;1 mg/kg prednisone or equivalent doses given for &gt;4
                  weeks or planned during intervention)

               -  immunosuppressive combination therapy with two or more drugs with different mode
                  of action

               -  hematopoietic stem cell transplantation within the past 6 months or planned
                  during treatment period

               -  solid organ transplant

               -  treatment with biologicals within the previous year

          -  Life expectancy &lt; 3 months

          -  Inability to take oral drugs

          -  Injection drug user

          -  Expected low compliance with drug regimen

          -  Participation in other interventional trials within the previous three months or
             ongoing

          -  Pregnant women and nursing mothers

          -  For premenopausal women: Failure to use highly-effective contraceptive methods for 1
             month after receiving study drug. The following contraceptive methods with a Pearl
             Index lower than 1% are regarded as highly-effective:

               -  oral hormonal contraception ('pill')

               -  dermal hormonal contraception

               -  vaginal hormonal contraception (NuvaRing®)

               -  contraceptive plaster

               -  long-acting injectable contraceptives

               -  implants that release progesterone (Implanon®)

               -  tubal ligation (female sterilisation)

               -  intrauterine devices that release hormones (hormone spiral)

               -  double barrier methods

          -  Persons with any kind of dependency on the investigator or employed by the sponsor or
             investigator

          -  Persons held in an institution by legal or official order
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Achim J Kaasch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heinrich-Heine University, Duesseldorf</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Achim J Kaasch, MD</last_name>
    <phone>+492118114758</phone>
    <email>achim.kaasch@hhu.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anna Rommerskirchen</last_name>
    <phone>+492118112496</phone>
    <email>anna.rommerskirchen@med.uni-duesseldorf.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Annecy</name>
      <address>
        <city>Annecy</city>
        <zip>74000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>J Gaillat, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chambéry</name>
      <address>
        <city>Chambéry</city>
        <zip>73000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>E Forestier, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>J P Stahl, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>La Roche-sur-Yon</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <zip>85000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>T Guimard, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>D Boutoille, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Orléans</name>
      <address>
        <city>Orléans</city>
        <zip>45100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>L Hocqeloux, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Paris 5</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>J Molina, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Paris 1</name>
      <address>
        <city>Paris</city>
        <zip>92100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>E Rouveix-Nordon, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Paris 3</name>
      <address>
        <city>Paris</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>B Fantin, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Paris 2</name>
      <address>
        <city>Paris</city>
        <zip>93000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>F Mechai, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Paris 4</name>
      <address>
        <city>Paris</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>R. Lepeule, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Quimper</name>
      <address>
        <city>Quimper</city>
        <zip>29107</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>J Tallarmin, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>P Tattevin, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Etienne</name>
      <address>
        <city>Saint Etienne</city>
        <zip>42800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>F Lucht, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tours</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>L Bernard, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>12157</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Keikawus Arastéh, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uniklinik Köln</name>
      <address>
        <city>Cologne</city>
        <zip>50935</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gerd Fätkenheuer, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Düsseldorf</name>
      <address>
        <city>Dusseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Achim J Kaasch, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Frankfurt</name>
      <address>
        <city>Frankfurt/Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christoph Stephan, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Winfried V Kern, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tobias Welte, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jena</name>
      <address>
        <city>Jena</city>
        <zip>07743</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Matthias Pletz, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Krefeld</name>
      <address>
        <city>Krefeld</city>
        <zip>47805</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Katrin Kösters, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leverkusen</name>
      <address>
        <city>Leverkusen</city>
        <zip>51375</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stefan Reuter, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lübeck</name>
      <address>
        <city>Lübeck</city>
        <zip>23562</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jan Rupp, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>VUmc Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Karin van Dijk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Breda</name>
      <address>
        <city>Breda</city>
        <zip>4814 CK Breda</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>UMC Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bhanu Sinha, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marjan Wouthuyzen-Bakker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tilburg</name>
      <address>
        <city>Tilburg</city>
        <zip>5022GC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marc Bonten, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Diakonessenhuis Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>5022</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Anneloes Vlek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barcelona II</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Barcelona I</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alex Soriano, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Palma</name>
      <address>
        <city>Palma de Mallorca</city>
        <zip>07010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mecholr Riera, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sevilla II</name>
      <address>
        <city>Sevilla</city>
        <zip>41071</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>José Cisneros, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sevilla</name>
      <address>
        <city>Sevilla</city>
        <zip>41071</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jesus Rodríguez-Baño, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nottingham</name>
      <address>
        <city>Nottingham</city>
        <zip>NG7 24 H</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2013</study_first_submitted>
  <study_first_submitted_qc>February 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2013</study_first_posted>
  <last_update_submitted>March 1, 2018</last_update_submitted>
  <last_update_submitted_qc>March 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Staphylococcus aureus</keyword>
  <keyword>Bloodstream infection</keyword>
  <keyword>Oral switch</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Staphylococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Clindamycin palmitate</mesh_term>
    <mesh_term>Clindamycin phosphate</mesh_term>
    <mesh_term>Linezolid</mesh_term>
    <mesh_term>Cefazolin</mesh_term>
    <mesh_term>Daptomycin</mesh_term>
    <mesh_term>Trimethoprim, Sulfamethoxazole Drug Combination</mesh_term>
    <mesh_term>Cloxacillin</mesh_term>
    <mesh_term>Floxacillin</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
    <mesh_term>Trimethoprim</mesh_term>
    <mesh_term>Sulfamethoxazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

